Proactiveinvestors United Kingdom Concepta https://www.proactiveinvestors.co.uk Proactiveinvestors United Kingdom Concepta RSS feed en Wed, 22 May 2019 19:55:31 +0100 http://blogs.law.harvard.edu/tech/rss Genera CMS action@proactiveinvestors.com (Proactiveinvestors) action@proactiveinvestors.com (Proactiveinvestors) <![CDATA[RNS press release - Notice of AGM ]]> https://www.proactiveinvestors.co.uk/companies/rns/14643/LSE20190521090001_14081593/ Tue, 21 May 2019 09:00:01 +0100 https://www.proactiveinvestors.co.uk/companies/rns/14643/LSE20190521090001_14081593/ <![CDATA[Media files - Concepta chairman sees significant opportunity for its myLotus fertility product ]]> https://www.proactiveinvestors.co.uk/companies/stocktube/13396/concepta-chairman-sees-significant-opportunity-for-its-mylotus-fertility-product-13396.html Fri, 17 May 2019 11:25:00 +0100 https://www.proactiveinvestors.co.uk/companies/stocktube/13396/concepta-chairman-sees-significant-opportunity-for-its-mylotus-fertility-product-13396.html <![CDATA[News - Concepta geared up for a commercially pivotal year ]]> https://www.proactiveinvestors.co.uk/companies/news/220334/concepta-geared-up-for-a-commercially-pivotal-year-220334.html Concepta is the healthcare group behind myLotus – an easy-to-use home test that has been developed for women who have been trying to conceive without any luck for at least six months.

It measures hormone levels in urine to identify the woman’s most fertile days and can also help to explain the apparent lack of fertility.

A smartphone app helps user keep track of their results, which can then be shared with doctors to help improve the chances of conception.

How it’s doing

Last October, myLotus received CE Mark certification, meaning it can be sold in the UK and Europe, as well as ISO manufacturing approval.

Towards the end of 2018, the test kit was launched in the UK, where it can now be found in Boots’ chemists after the two companies struck a deal in March.

With the UK launch now complete, the plan is to roll out myLotus across Europe, and Concepta recently raised £2.2mln to help it do just that.

“The market opportunity for myLotus in fertility, pregnancy and women's health is substantial and with limited direct competition, the board believes Concepta has strong prospects for growth,” said chairman Matthew Walls.

“We are at the early stages of our product launch and program build and we will continue to educate users on the value of myLotus, raise brand awareness and bolster our sales and marketing expertise over the coming year.”

The testimonials from early adopters have also been glowing (click here).

Inflexion points

The priorities this year are to progress the UK consumer and business-to-business channels and focus on potential partnerships with diagnostics groups, while creating additional tests.

In a recent update it set out its goals as follows:

Development of a sustainable revenue growth model EU roll-out to take advantage of our CE Mark approval and eCommerce platform capability Expand the collaboration with Boots UK and the Walgreens Boots Alliance Piloting of myLotus for use in IVF Piloting of myLotus fertility and pregnancy support journey Bluetooth capability and improved display  Development of new hormone tests What the chairman says…

“Based on our increasing pregnancies and user testimonials, we expect to raise the profile of myLotus over the coming year and take advantage of our new technology innovation and industry know-how to drive our growth strategy,” said Matthew Walls.

]]>
Wed, 15 May 2019 14:33:00 +0100 https://www.proactiveinvestors.co.uk/companies/news/220334/concepta-geared-up-for-a-commercially-pivotal-year-220334.html
<![CDATA[News - Concepta hails early success of fertility product as makes significant commercial progress ]]> https://www.proactiveinvestors.co.uk/companies/news/220190/concepta-hails-early-success-of-fertility-product-as-makes-significant-commercial-progress-220190.html Concepta PLC (LON:CPTA) shares rose on Tuesday as the firm coupled annual results with news of early successes for its myLotus fertility product for couples in the early stages of trying to conceive.

The self-test product went on sale last year and a supply agreement was struck with Boots in the UK in March.

“The market opportunity for myLotus in fertility, pregnancy and women's health is substantial and with limited direct competition, the board believes Concepta has strong prospects for growth,” said chairman Matthew Walls.

“We are at the early stages of our product launch and program build and we will continue to educate users on the value of myLotus, raise brand awareness and bolster our sales and marketing expertise over the coming year,” he added.

READ: myLotus testimonials 

Results for the 12 months ended December 31 charted a period of operational progress including CE Mark certification (European sign-off for the device) and ISO manufacturing approval. The company also launched the www.myLotus.com e-commerce site.

During the year Concepta appointed Walls as chairman and Peter Dines, from largest shareholder Mercia Technologies, as an independent director, while David Darrock became chief operating officer.

As is common for companies at this formative stage of its commercial development, Concepta was loss-making – to the tune of £2.65mln on an underlying earnings (EBITDA) basis.

Cash at the year-end was £740,000, which was supplemented by a further £2.2mln, raised at 3p a share in April.

“Our priority for 2019 is to develop our UK sales channels in B2C and B2B and engage a sustainable growth model which we can extend across the EU,” said Walls.

“We will also develop our strategic relationships with large diagnostic groups capable of internationally exploiting our diagnostic platform across personalised health and wellbeing.”

In afternoon trading, Concepta shares were 4.4% higher at 3.55p.

 -- Adds share price --

]]>
Tue, 14 May 2019 07:53:00 +0100 https://www.proactiveinvestors.co.uk/companies/news/220190/concepta-hails-early-success-of-fertility-product-as-makes-significant-commercial-progress-220190.html
<![CDATA[RNS press release - Annual Results ]]> https://www.proactiveinvestors.co.uk/companies/rns/14643/LSE20190514070102_14072489/ Tue, 14 May 2019 07:01:02 +0100 https://www.proactiveinvestors.co.uk/companies/rns/14643/LSE20190514070102_14072489/ <![CDATA[RNS press release - Concepta announces first myLotus® pregnancies ]]> https://www.proactiveinvestors.co.uk/companies/rns/14643/LSE20190514070005_14072392/ Tue, 14 May 2019 07:00:05 +0100 https://www.proactiveinvestors.co.uk/companies/rns/14643/LSE20190514070005_14072392/ <![CDATA[RNS press release - Holding(s) in Company ]]> https://www.proactiveinvestors.co.uk/companies/rns/14643/LSE20190430162855_14057960/ Tue, 30 Apr 2019 16:28:55 +0100 https://www.proactiveinvestors.co.uk/companies/rns/14643/LSE20190430162855_14057960/ <![CDATA[RNS press release - TR-1: form for notification of major holdings ]]> https://www.proactiveinvestors.co.uk/companies/rns/14643/LSE20190430134656_14057646/ Tue, 30 Apr 2019 13:46:56 +0100 https://www.proactiveinvestors.co.uk/companies/rns/14643/LSE20190430134656_14057646/ <![CDATA[RNS press release - TR-1: notification of major holdings ]]> https://www.proactiveinvestors.co.uk/companies/rns/14643/LSE20190429132045_14055725/ Mon, 29 Apr 2019 13:20:45 +0100 https://www.proactiveinvestors.co.uk/companies/rns/14643/LSE20190429132045_14055725/ <![CDATA[RNS press release - Director/PDMR Shareholding ]]> https://www.proactiveinvestors.co.uk/companies/rns/14643/LSE20190426105259_14053591/ Fri, 26 Apr 2019 10:52:59 +0100 https://www.proactiveinvestors.co.uk/companies/rns/14643/LSE20190426105259_14053591/ <![CDATA[RNS press release - Result of Meeting ]]> https://www.proactiveinvestors.co.uk/companies/rns/14643/LSE20190425110735_14051943/ Thu, 25 Apr 2019 11:07:35 +0100 https://www.proactiveinvestors.co.uk/companies/rns/14643/LSE20190425110735_14051943/ <![CDATA[News - Concepta raises £2.3mln to help fund international launches of MyLotus ]]> https://www.proactiveinvestors.co.uk/companies/news/218121/concepta-raises-23mln-to-help-fund-international-launches-of-mylotus-218121.html Concepta PLC (LON:CPT) has conditionally raised £2.3mln to help take its flagship myLotus fertility testing kit around the world.

The AIM company recently launched the home-test kit, which allows women to identify their most fertile days, in the UK, where it can be found in Boots’ chemists.

READ: Concepta jumps as it inks deal to sell myLotus in Boots' chemists

But bosses have moved to arm themselves with plenty of cash as they seek similar launches in other territories.

“The past six months have seen the company successfully complete its clinical studies, gain regulatory approval and launch its first myLotus product,” said chairman Matthew Walls.

“Following the recent Boots UK announcement, we will be extending our digital marketing across the EU under our CE certification.”

He added: “It is an exciting time for the company and the placing funds will continue to strengthen and accelerate our commercial plans.”

Chairman and CFO invest

Concepta has raised the money by issuing shares at 3p apiece – a 13% discount to Friday’s closing price.

Major shareholder Mercia Technologies PLC (LON:MERC) took part in the placing, as did chairman Walls and chief financial officer Barbara Spurrier.

Because the new shares will represent almost 29% of the total share capital once issued, Concepta needs approval from shareholders at a general meeting later this month.

]]>
Mon, 08 Apr 2019 07:55:00 +0100 https://www.proactiveinvestors.co.uk/companies/news/218121/concepta-raises-23mln-to-help-fund-international-launches-of-mylotus-218121.html
<![CDATA[RNS press release - Placing to raise £2.3m; Notice of General Meeting ]]> https://www.proactiveinvestors.co.uk/companies/rns/14643/LSE20190408070006_14031624/ Mon, 08 Apr 2019 07:00:06 +0100 https://www.proactiveinvestors.co.uk/companies/rns/14643/LSE20190408070006_14031624/ <![CDATA[RNS press release - Concepta to supply myLotus® to Boots UK ]]> https://www.proactiveinvestors.co.uk/companies/rns/14643/LSE20190329070002_14020367/ Fri, 29 Mar 2019 07:00:02 +0000 https://www.proactiveinvestors.co.uk/companies/rns/14643/LSE20190329070002_14020367/ <![CDATA[News - Concepta jumps as it inks deal to sell myLotus in Boots' chemists ]]> https://www.proactiveinvestors.co.uk/companies/news/216256/concepta-jumps-as-it-inks-deal-to-sell-mylotus-in-boots--chemists-216256.html Concepta PLC (LON:CPT) shares jumped in mid-morning trading Tuesday after it inked an agreement to supply its myLotus fertility testing kit to high street chemist Boots.

The healthcare firm said the agreement with Walgreens Boots Alliance Inc (NASDAQ:WBA),  which owns both Boots and US pharmacy chain Walgreens, would allow it to supply Boots stores in the UK as well as other WBA partners across EU markets that use the CE-Mark, a quality standard for the European Economic Area that myLotus achieved last October.

READ: Concepta hails successful UK launch of myLotus fertility testing product

myLotus is a self-testing kit that allows women to measure their fertility levels and determine when they are most likely to become pregnant naturally, offering an alternative to expensive treatments like in-vitro fertilisation (IVF).

Matthew Walls, chairman of Concepta, said the firm was “delighted to work with such a respected British high-street brand” and was now preparing its roll-out plans for the EU market.

Investor hails deal as “validation” of myLotus appeal

In a separate announcement, Mercia Technologies PLC (LON:MERC), an investment group that owns an 18.2% stake in Concepta, hailed the deal as “validation” that the myLotus product had “significant commercial appeal”.

“This new partnership will play a pivotal role in myLotus being more widely available across the UK and overseas", said Peter Dines, Mercia’s chief operating officer who is also a non-executive director of Concepta.

Shares were up 4% at 3.95p.

--Adds share price--

]]>
Tue, 12 Mar 2019 07:54:00 +0000 https://www.proactiveinvestors.co.uk/companies/news/216256/concepta-jumps-as-it-inks-deal-to-sell-mylotus-in-boots--chemists-216256.html
<![CDATA[RNS press release - Concepta to supply myLotus® to Walgreens Boots ]]> https://www.proactiveinvestors.co.uk/companies/rns/14643/LSE20190312070022_13998153/ Tue, 12 Mar 2019 07:00:22 +0000 https://www.proactiveinvestors.co.uk/companies/rns/14643/LSE20190312070022_13998153/ <![CDATA[News - Concepta hails successful UK launch of myLotus fertility testing product ]]> https://www.proactiveinvestors.co.uk/companies/news/211297/concepta-hails-successful-uk-launch-of-mylotus-fertility-testing-product-211297.html Concepta PLC (LON:CPT) has successfully launched in the UK its myLotus testing product for women’s fertility.

The myLotus home-test device allows women to identify their optimal fertile days thereby improving their chances of naturally getting pregnant.

"myLotus could empower you with some properly useful, personal fertility information which may well help you make decisions going forward and COULD help you conceive. We are all so different; this is why #myLotusFertility is brilliant" @thisisalicerosehttps://t.co/RaWCeUQgYO pic.twitter.com/9ittIrFxs6

— myLotusFertility (@myLotusMonitor) December 11, 2018

The profile and sales of the myLotus device are just commencing but feedback from early users and fertility bloggers has been very positive, Concepta said.

“We will be raising awareness of the value of the myLotus device and its window on fertility over the coming months via an increased online presence, Key Opinion Leaders and marketing of our initial fertility case studies,” said Matthew Walls, the chairman of Concepta.

]]>
Mon, 17 Dec 2018 07:37:00 +0000 https://www.proactiveinvestors.co.uk/companies/news/211297/concepta-hails-successful-uk-launch-of-mylotus-fertility-testing-product-211297.html
<![CDATA[RNS press release - myLotus® successful UK launch ]]> https://www.proactiveinvestors.co.uk/companies/rns/14643/LSE20181217070005_13905275/ Mon, 17 Dec 2018 07:00:05 +0000 https://www.proactiveinvestors.co.uk/companies/rns/14643/LSE20181217070005_13905275/ <![CDATA[News - Concepta readies for imminent UK launch of myLotus in first milestone of European strategy ]]> https://www.proactiveinvestors.co.uk/companies/news/208231/concepta-readies-for-imminent-uk-launch-of-mylotus-in-first-milestone-of-european-strategy-208231.html Healthcare firm Concepta PLC (LON:CPT) has said it will launch its myLotus product range in the UK at the start of November at the Fertility Show in London.

MyLotus is an easy-to-use home test that has been developed for women who have been trying to conceive for six months or more.

READ: Concepta to launch myLotus in UK at Fertility Show in November

It measures hormone levels in urine to give quantitative and qualitative measurements that might help explain the apparent lack of fertility.

In late October, the company said the myLotus range had received CE-Mark certification, allowing its sale in the UK, the EU, and the European Economic Area (EEA).

Once the UK roll-out is completed, the plan is to then to start selling myLotus across Europe.

Switch in focus

China had been the initial focus for Concepta but progress there has been “disappointing” and so new executive chairman Matthew Walls, who joined in July, has decided to switch tack.

Walls formerly served as the global commercial director of FTSE 100 pharma giant AstraZeneca PLC (LON:AZN), but has also worked in the small-cap pharma and biotech space as chief executive for molecular diagnostics and fellow AIM-listee Genedrive PLC (LON:GDR).

“Whilst the positive study results from the Changhai hospital, Shanghai have helped bolster our confidence in the China product, given our limited bandwidth and revenue growth objectives, our efforts will be aligned to support the successful launch of myLotus in the UK,” said Walls in the company’s half-year report in September.

READ: Concepta switches focus to UK where it is gearing up for ‘imminent’ myLotus launch

For the six months ended June 30, Concepta posted a loss of £1.49mln (H1 17: £1.08mln), reflecting the cost of getting myLotus ready for its UK launch.

The company ended the period with almost £250,000 (H1 17: £1.23mln), although a £2mln placing in August means that figure is likely looking a bit healthier now.

The strategy does not mean the firm is completely out of China, however, as its deal with SinoPharm, the largest state-owned pharmaceutical company in China, to supply myLotus meters is scheduled to run at least until the end of 2018.

With shares trading around 4p, Concepta carries a market cap of around £7mln.

]]>
Wed, 31 Oct 2018 09:00:00 +0000 https://www.proactiveinvestors.co.uk/companies/news/208231/concepta-readies-for-imminent-uk-launch-of-mylotus-in-first-milestone-of-european-strategy-208231.html
<![CDATA[News - Concepta surges on news of UK myLotus launch ]]> https://www.proactiveinvestors.co.uk/companies/news/208202/concepta-surges-on-news-of-uk-mylotus-launch-208202.html Concepta PLC (LON:CPT) shares surged in lunchtime trading Wednesday after it said it will launch its myLotus product in the UK at the Fertility Show in London, to be held on the 3rd and 4th of November.

The healthcare group said its stand at the show, to be held in Olympia, will also include representation from key opinion leaders, fertility doctors and health experts who will answer questions on myLotus products.

READ: Concepta jumps as myLotus products receive CE-Mark certification

Earlier this week, Concepta said that its myLotus product range, which helps women monitor their fertility levels, had received CE-Mark certification from regulators, allowing its sale in the UK.

Matthew Walls, chairman of Concepta, said women attending the show would be able to exclusively buy a Starter Pack, consisting of a myLotus monitor, 3 packs of 20 ovulation tests and 3 packs of 3 pregnancy tests, at the 'Special Launch' price of £199.

He added that the products would also be made available online.

Shares were up 8.1% at 4p.

-- Adds share price --

]]>
Wed, 31 Oct 2018 07:57:00 +0000 https://www.proactiveinvestors.co.uk/companies/news/208202/concepta-surges-on-news-of-uk-mylotus-launch-208202.html
<![CDATA[RNS press release - myLotus® launch at The Fertility Show, London ]]> https://www.proactiveinvestors.co.uk/companies/rns/14643/LSE20181031070005_13848506/ Wed, 31 Oct 2018 07:00:05 +0000 https://www.proactiveinvestors.co.uk/companies/rns/14643/LSE20181031070005_13848506/ <![CDATA[News - Concepta jumps as myLotus products receive CE-Mark certification ]]> https://www.proactiveinvestors.co.uk/companies/news/207993/concepta-jumps-as-mylotus-products-receive-ce-mark-certification-207993.html Concepta PLC’s (LON:CPT) shares jumped in early trading Monday as its myLotus product range received CE-Mark certification, enabling its sale in the UK market.

The healthcare firm said the products, which allow women to self-test their fertility levels, would be launched through its new eCommerce platform to service initial demand.

READ: Concepta switches focus to UK where it is gearing up for ‘imminent’ myLotus launch

The myLotus products would also be available to women who are planning to start a family or who had previously struggled to naturally conceive.

The product range is expected to launch in the UK in the next few months.

Matthew Walls, chairman of Concepta, said the firm was “delighted” to receive the CE certification and would advise on the timing of the UK product launch “very shortly”.

Shares were up 11.6% at 3.3p.

 -- Adds share price --

]]>
Mon, 29 Oct 2018 07:24:00 +0000 https://www.proactiveinvestors.co.uk/companies/news/207993/concepta-jumps-as-mylotus-products-receive-ce-mark-certification-207993.html
<![CDATA[RNS press release - myLotus gains CE-mark regulatory approval ]]> https://www.proactiveinvestors.co.uk/companies/rns/14643/LSE20181029070007_13845086/ Mon, 29 Oct 2018 07:00:07 +0000 https://www.proactiveinvestors.co.uk/companies/rns/14643/LSE20181029070007_13845086/ <![CDATA[RNS press release - Holding(s) in Company ]]> https://www.proactiveinvestors.co.uk/companies/rns/14643/LSE20181005144241_13818789/ Fri, 05 Oct 2018 14:42:41 +0100 https://www.proactiveinvestors.co.uk/companies/rns/14643/LSE20181005144241_13818789/ <![CDATA[RNS press release - Grant of Options ]]> https://www.proactiveinvestors.co.uk/companies/rns/14643/LSE20180928070011_13808053/ Fri, 28 Sep 2018 07:00:11 +0100 https://www.proactiveinvestors.co.uk/companies/rns/14643/LSE20180928070011_13808053/ <![CDATA[RNS press release - Second Price Monitoring Extn ]]> https://www.proactiveinvestors.co.uk/companies/rns/14643/LSE20180927164133_13807737/ Thu, 27 Sep 2018 16:41:33 +0100 https://www.proactiveinvestors.co.uk/companies/rns/14643/LSE20180927164133_13807737/ <![CDATA[RNS press release - Price Monitoring Extension ]]> https://www.proactiveinvestors.co.uk/companies/rns/14643/LSE20180927163730_13807726/ Thu, 27 Sep 2018 16:37:30 +0100 https://www.proactiveinvestors.co.uk/companies/rns/14643/LSE20180927163730_13807726/ <![CDATA[News - Concepta switches focus to UK where it is gearing up for ‘imminent’ myLotus launch ]]> https://www.proactiveinvestors.co.uk/companies/news/205830/concepta-switches-focus-to-uk-where-it-is-gearing-up-for-imminent-mylotus-launch-205830.html Concepta PLC (LON:CPT) is to focus more of its resources on the UK, where it expects to launch its myLotus fertility product within the next few months.

MyLotus is an easy-to-use home test that has been developed for women who have been trying to conceive for six months or more.

It measures hormone levels in urine to give quantitative and qualitative measurements that might help explain the apparent lack of fertility.

READ: Concepta raises £2mln

The AIM-quoted firm is currently waiting on the receipt of a CE mark which will allow it to sell the product throughout the UK and Europe.

China had been the initial focus for Concepta but progress there has been “disappointing” and so new executive chairman Matthew Walls, who joined in July, has decided to switch tack.

“Whilst the positive study results from the Changhai hospital, Shanghai have helped bolster our confidence in the China product, given our limited bandwidth and revenue growth objectives our efforts will be aligned to support the successful launch of myLotus in the UK,” said Walls in Thursday’s half-year report.

Once the UK roll-out is completed, the plan is to then to start selling myLotus across Europe.

For the six months ended June 30, Concepta posted a loss of £1.49mln (H1 17: £1.08mln), reflecting the cost of getting myLotus ready for its UK launch.

The company ended the period with almost £250,000 (H1 17: £1.23mln), although a £2mln placing in August means that figure is likely looking a bit healthier now.

]]>
Thu, 27 Sep 2018 07:54:00 +0100 https://www.proactiveinvestors.co.uk/companies/news/205830/concepta-switches-focus-to-uk-where-it-is-gearing-up-for-imminent-mylotus-launch-205830.html
<![CDATA[RNS press release - Directorate change ]]> https://www.proactiveinvestors.co.uk/companies/rns/14643/LSE20180927070103_13806295/ Thu, 27 Sep 2018 07:01:03 +0100 https://www.proactiveinvestors.co.uk/companies/rns/14643/LSE20180927070103_13806295/ <![CDATA[RNS press release - Interim Results ]]> https://www.proactiveinvestors.co.uk/companies/rns/14643/LSE20180927070009_13806206/ Thu, 27 Sep 2018 07:00:09 +0100 https://www.proactiveinvestors.co.uk/companies/rns/14643/LSE20180927070009_13806206/ <![CDATA[RNS press release - Holding(s) in Company ]]> https://www.proactiveinvestors.co.uk/companies/rns/14643/LSE20180921094709_13799933/ Fri, 21 Sep 2018 09:47:09 +0100 https://www.proactiveinvestors.co.uk/companies/rns/14643/LSE20180921094709_13799933/ <![CDATA[RNS press release - Holding(s) in Company ]]> https://www.proactiveinvestors.co.uk/companies/rns/14643/LSE20180828070007_13768714/ Tue, 28 Aug 2018 07:00:07 +0100 https://www.proactiveinvestors.co.uk/companies/rns/14643/LSE20180828070007_13768714/ <![CDATA[RNS press release - Holding(s) in Company ]]> https://www.proactiveinvestors.co.uk/companies/rns/14643/LSE20180813125518_13753320/ Mon, 13 Aug 2018 12:55:18 +0100 https://www.proactiveinvestors.co.uk/companies/rns/14643/LSE20180813125518_13753320/ <![CDATA[RNS press release - Holding(s) in Company ]]> https://www.proactiveinvestors.co.uk/companies/rns/14643/LSE20180813070003_13752178/ Mon, 13 Aug 2018 07:00:03 +0100 https://www.proactiveinvestors.co.uk/companies/rns/14643/LSE20180813070003_13752178/ <![CDATA[RNS press release - Holding(s) in Company ]]> https://www.proactiveinvestors.co.uk/companies/rns/14643/LSE20180809121528_13750100/ Thu, 09 Aug 2018 12:15:28 +0100 https://www.proactiveinvestors.co.uk/companies/rns/14643/LSE20180809121528_13750100/ <![CDATA[News - Concepta raises £2mln to accelerate myLotus expansion in China ]]> https://www.proactiveinvestors.co.uk/companies/news/202068/concepta-raises-2mln-to-accelerate-mylotus-expansion-in-china-202068.html Concepta PLC (LON:CPT) has raised £2mln in an oversubscribed share placing to fund the expansion of its myLotus product in the Chinese market.

The AIM-listed fertility products manufacturer said it had raised the funds through the placing of 50mln new ordinary shares at a placing price of 4p each, an almost 14% discount to its last close price of 4.65p.

READ: Concepta appoints former CEO of Genedrive as new chairman

Concepta said the proceeds would be used to accelerate the expansion of the myLotus product in China by targeting an estimated market of 2.3mln women per year across the areas of Hebei, Shanghai, Beijing, Shangdong, Henan and Liaoning through initial distributor agreements.

The group added that the funds would also be used to help advance its launch of myLotus in the European market, initially through online channels to consumers in the UK and Germany.

Matthew Walls, chairman of Concepta, said that despite a delay in engaging the myLotus product in the Chinese market, “the prospective milestones of regulatory approval, completed clinical studies and growing sales are significant and will anchor the group for accelerated future growth”.

]]>
Thu, 02 Aug 2018 07:19:00 +0100 https://www.proactiveinvestors.co.uk/companies/news/202068/concepta-raises-2mln-to-accelerate-mylotus-expansion-in-china-202068.html
<![CDATA[RNS press release - Oversubscribed placing raises £2,000,000 ]]> https://www.proactiveinvestors.co.uk/companies/rns/14643/LSE20180802070015_13740638/ Thu, 02 Aug 2018 07:00:15 +0100 https://www.proactiveinvestors.co.uk/companies/rns/14643/LSE20180802070015_13740638/ <![CDATA[News - Concepta appoints former CEO of Genedrive as new chairman ]]> https://www.proactiveinvestors.co.uk/companies/news/200909/concepta-appoints-former-ceo-of-genedrive-as-new-chairman-200909.html Concepta PLC (LON:CPT) has appointed the former chief executive of Genedrive PLC (LON:GDR) as its new chairman while also appointing a new non-executive director.

The AIM-listed fertility aid manufacturer said Matthew Walls would become chairman of the company with immediate effect, while former chairman Adam Reynolds would move to the role of non-executive director.

WATCH: Concepta PLC making progress after steep learning curve in China

Walls previously held roles as chief executive and chairman of patient behavioural change company Atlantis Healthcare Group, chairman and advisory roles for The Fertility Partnership, the UK’s largest fertility group, as well as chief executive of AIM-listed molecular diagnostics company Genedrive.

Walls also held the role of global commercial director at FTSE 100 pharma giant AstraZeneca PLC (LON:AZN), with commercial and financial responsibility for strategy and international business operations.

Erik Henau, Concepta chief executive, said: "[Walls’] fantastic track record in achieving commercial success and knowledge of corporate governance, regulatory issues, and delivery of strategic plans in the healthcare arena will be instrumental to Concepta as it enters this important phase in its expansion.”

The firm also said it had appointed Peter Dines, the current chief operating officer & head of life sciences and biosciences at Marcia Technologies, Concepta’s major shareholder, as a non-executive director with immediate effect while Dr Mark Wyatt would step down from his own non-executive director role to focus on other business interests.

Henau said: “With over 20 years' experience in managing growth businesses in the healthcare and pharma sector, Peter will be a welcome addition to the Board and will further strengthen our team as we continue to scale the business.”

]]>
Tue, 17 Jul 2018 07:23:00 +0100 https://www.proactiveinvestors.co.uk/companies/news/200909/concepta-appoints-former-ceo-of-genedrive-as-new-chairman-200909.html
<![CDATA[RNS press release - Board Changes ]]> https://www.proactiveinvestors.co.uk/companies/rns/14643/LSE20180717070011_13719907/ Tue, 17 Jul 2018 07:00:11 +0100 https://www.proactiveinvestors.co.uk/companies/rns/14643/LSE20180717070011_13719907/ <![CDATA[RNS press release - Result of AGM ]]> https://www.proactiveinvestors.co.uk/companies/rns/14643/LSE20180614102215_13679665/ Thu, 14 Jun 2018 10:22:15 +0100 https://www.proactiveinvestors.co.uk/companies/rns/14643/LSE20180614102215_13679665/ <![CDATA[RNS press release - Notice of AGM ]]> https://www.proactiveinvestors.co.uk/companies/rns/14643/LSE20180522171318_13651129/ Tue, 22 May 2018 17:13:18 +0100 https://www.proactiveinvestors.co.uk/companies/rns/14643/LSE20180522171318_13651129/ <![CDATA[Media files - Concepta PLC making progress after steep learning curve in China ]]> https://www.proactiveinvestors.co.uk/companies/stocktube/9178/concepta-plc-making-progress-after-steep-learning-curve-in-china-9178.html Tue, 01 May 2018 12:58:00 +0100 https://www.proactiveinvestors.co.uk/companies/stocktube/9178/concepta-plc-making-progress-after-steep-learning-curve-in-china-9178.html <![CDATA[News - Concepta believes component supply issues have been sorted ]]> https://www.proactiveinvestors.co.uk/companies/news/196121/concepta-believes-component-supply-issues-have-been-sorted-196121.html Fertility aid manufacturer Concepta PLC (LON:CPT) believes it has sorted the supply side problems in China that hit its numbers in 2017.

Problems getting the components for its MyLotus test meant a US$600,000 order was delayed and still has not been delivered.

WATCH: Concepta PLC making progress after steep learning curve in China

Concepta said it will not deliver on the order until it receives payment but had now reviewed and audited its supply chain to ensure that all future orders will be on time.

Securing a few key successful distribution channels will deliver robust revenue growth in 2018, it added in a statement.

Earlier this month, the group signed a distribution agreement with one of China’s largest pharma groups, SinoPharm, which will mean regular orders and upfront payments said Erik Henau, chief executive.

Adam Reynolds, chairman added: “Launching a new product into a new market is a complex process and, although progress has been slower than anticipated, we have built robust foundations in China and are well on our way to launching in the EU. 

“The hospital trials undertaken in China were hugely successful, demonstrating that myLotus offers exceptional correlation with laboratory blood tests and that it can help women who experience weaker positives to determine when they are most fertile.”

Sales in 2017 were £108,000, with a loss of £2.45mln, while cash at the year-end of £1.54mln.

]]>
Tue, 01 May 2018 08:14:00 +0100 https://www.proactiveinvestors.co.uk/companies/news/196121/concepta-believes-component-supply-issues-have-been-sorted-196121.html
<![CDATA[RNS press release - Final Results ]]> https://www.proactiveinvestors.co.uk/companies/rns/14643/LSE20180501070004_13624769/ Tue, 01 May 2018 07:00:04 +0100 https://www.proactiveinvestors.co.uk/companies/rns/14643/LSE20180501070004_13624769/ <![CDATA[News - Concepta shares surge as it signs logistics agreement with SinoPharm for myLotus distribution ]]> https://www.proactiveinvestors.co.uk/companies/news/195846/concepta-shares-surge-as-it-signs-logistics-agreement-with-sinopharm-for-mylotus-distribution-195846.html Concepta PLC (LON:CPT) shares surged 26% higher on Thursday as the firm signed an agreement with SinoPharm, the largest state-owned pharmaceutical company in China for local stock holdings and logistics services throughout the whole of the country for its fertility product myLotus.

Under the terms of the deal, the AIM-listed firm will receive regular quarterly orders for myLotus meters from SinoPharm, with 50% of the payment made upfront and 50% paid on delivery.

READ: Concepta achieves certification for producing myLotus product at Doncaster facility

SinoPharm - which has annual sales of over £23bn - will coordinate the logistics and distribution of units with Concepta’s China office executing the marketing plan.

The UK healthcare company said the contract will run to 31 December 2018 and will be renewed on a yearly rolling basis thereafter.

Concepta also reported that, given previous delays, it was not possible to fulfil any orders in the first quarter of 2018, therefore payments have not been forthcoming and will no longer be relied upon in the company’s 2018 plans.

Eric Henau, CEO of Concepta, commented: “This key strategic deal clearly reflects our revised strategy and will provide us with regular orders and upfront payment from a highly-respected and well-placed trade partner in the market.”

He added: “The deal offers us greater flexibility in the Chinese market as stock will be readily available rather than having to be manufactured to order.”

“We are confident that this focus on establishing a few key successful distribution channels will deliver strong revenue growth in 2018,” Henau concluded.

In late morning trading, Concepta’s shares leapt 26% higher to 7.9p.

]]>
Thu, 26 Apr 2018 10:51:00 +0100 https://www.proactiveinvestors.co.uk/companies/news/195846/concepta-shares-surge-as-it-signs-logistics-agreement-with-sinopharm-for-mylotus-distribution-195846.html
<![CDATA[RNS press release - Logistics deal with major Chinese player SinoPharm ]]> https://www.proactiveinvestors.co.uk/companies/rns/14643/LSE20180426100004_13619769/ Thu, 26 Apr 2018 10:00:04 +0100 https://www.proactiveinvestors.co.uk/companies/rns/14643/LSE20180426100004_13619769/ <![CDATA[News - Concepta achieves certification for producing myLotus product at Doncaster facility ]]> https://www.proactiveinvestors.co.uk/companies/news/194496/concepta-achieves-certification-for-producing-mylotus-product-at-doncaster-facility-194496.html Concepta PLC (LON:CPT) has achieved the certification necessary for manufacturing the myLotus fertility product at its facility in Doncaster.

The AIM-listed firm said that ISO123485 certification allows the company to utilise the automated production lines recently installed at the Doncaster facility to begin manufacturing the diagnostic tests.

READ: Concepta receives ‘excellent consumer feedback’ at myLotus fertility product pre-launch event in Manchester

Erik Henau, CEO of Concepta, said: “It is a great achievement for the team to reach this key milestone following the myLotus prelaunch in the UK.”

He added: “This development is important in enabling the company to operate with greater capacity and improved efficiency at one site and is a crucial step towards offering myLotus direct to consumers here in the UK.”

The company also announced that it expects to transfer the remaining manual assembly capability, currently located at the Colworth labs, to the Doncaster facility during April 2018.

The healthcare firm said this will enable all manufacturing capacity to be operated from the specially designed facility.

]]>
Mon, 09 Apr 2018 09:01:00 +0100 https://www.proactiveinvestors.co.uk/companies/news/194496/concepta-achieves-certification-for-producing-mylotus-product-at-doncaster-facility-194496.html
<![CDATA[RNS press release - Concepta manufacturing site achieves certification ]]> https://www.proactiveinvestors.co.uk/companies/rns/14643/LSE20180409082528_13596380/ Mon, 09 Apr 2018 08:25:28 +0100 https://www.proactiveinvestors.co.uk/companies/rns/14643/LSE20180409082528_13596380/ <![CDATA[News - Concepta receives ‘excellent consumer feedback’ at myLotus fertility product pre-launch event in Manchester ]]> https://www.proactiveinvestors.co.uk/companies/news/194001/concepta-receives-excellent-consumer-feedback-at-mylotus-fertility-product-pre-launch-event-in-manchester-194001.html Concepta PLC (LON:CPT) announced that it has showcased myLotus fertility products at the Manchester Fertility Show on 24 and 25 March 2018 and received an "excellent consumer feedback."

The AIM-listed firm said it has announced the forthcoming launch of myLotus products in the UK at the event which was attended by 53 specialised fertility exhibitors and approximately 1,200 people with fertility issues.

READ: Concepta to commence UK trials for myLotus fertility product after Ethics Committee approval

Erik Henau, CEO of Concepta, said: “The event was a great success and consumer feedback has been excellent, with many women and fertility support groups registering to be kept updated on the launch date of myLotus in the UK.”

The healthcare company, specialising in women’s fertility, said it is currently in the final stages of the CE-marking process for myLotus and the product is expected to be available in the UK in the second half of 2018, once the final audit by the British Standards Institution is complete.

Erik Henau concluded: “Having launched our myLotus website, our focus is now on driving marketing and raising further awareness of Concepta and myLotus products in our home market, in anticipation of its launch in the later half of the year.  

]]>
Thu, 29 Mar 2018 07:29:00 +0100 https://www.proactiveinvestors.co.uk/companies/news/194001/concepta-receives-excellent-consumer-feedback-at-mylotus-fertility-product-pre-launch-event-in-manchester-194001.html
<![CDATA[RNS press release - Concepta pre-launch myLotus in the UK ]]> https://www.proactiveinvestors.co.uk/companies/rns/14643/LSE20180329070012_13586020/ Thu, 29 Mar 2018 07:00:12 +0100 https://www.proactiveinvestors.co.uk/companies/rns/14643/LSE20180329070012_13586020/